{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:26:23Z","timestamp":1790375183811,"version":"4.1.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"24","license":[{"start":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T00:00:00Z","timestamp":1573862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Sanofi; Regeneron Pharmaceuticals, Inc."},{"name":"Fondation Assistance Publique-H\u00f4pitaux de Paris"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Lowering low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular risk irrespective of age, but the evidence is less strong for older patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>This prespecified analysis from ODYSSEY OUTCOMES compared the effect of alirocumab vs. placebo in 18\u00a0924 patients with recent acute coronary syndrome (ACS) according to age. We examined the effect of assigned treatment on occurrence of the primary study outcome, a composite of coronary heart disease death, myocardial infarction, ischaemic stroke, or unstable angina requiring hospitalization [major adverse cardiovascular event (MACE)] and all-cause death. Relative risk reductions were consistent for patients \u226565 vs. &amp;lt;65\u2009years for MACE [hazard ratio (HR) 0.78, 95% confidence interval (CI) 0.68\u20130.91 vs. 0.89, 0.80\u20131.00; P \u00a0interaction\u2009=\u20090.19] and all-cause death [HR 0.77, 0.62\u20130.95 vs. 0.94, 0.77\u20131.15; P \u00a0interaction\u2009=\u20090.46], and consistent for MACE when dichotomizing at age 75 years (HR 0.85, 0.64\u20131.13 in \u226575 vs. 0.85, 0.78\u20130.93 in &amp;lt;75, P \u00a0interaction\u2009=\u20090.19). When considering age as a continuous variable in regression models, advancing age increased risk of MACE, as well as the absolute reduction in MACE with alirocumab, with numbers-needed-to-treat for MACE at 3\u2009years of 43 (25\u2013186) at age 45 years, 26 (15\u201397) at age 75 years, and 12 (6\u201381) for those at age 85 years. Although adverse events were more frequent in older patients, there were no differences between alirocumab and placebo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In patients with recent ACS, alirocumab improves outcomes irrespective of age. Increasing absolute benefit but not harm with advancing age suggests that LDL-C lowering is an important preventive intervention for older patients after ACS.<\/jats:p>\n                  <jats:p\/>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehz809","type":"journal-article","created":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T20:10:47Z","timestamp":1572379847000},"page":"2248-2258","source":"Crossref","is-referenced-by-count":80,"title":["Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4716-5892","authenticated-orcid":false,"given":"Peter R","family":"Sinnaeve","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, University Hospitals Leuven , Herestraat 49, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory G","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Colorado School of Medicine , Box B130, Aurora, CO 80045, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M","family":"Wojdyla","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Division of Cardiology, Duke University Medical Center , 200 Morris Street, Durham, NC 27701, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Alings","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Amphia Ziekenhuis Molengracht , 4818 CK Breda, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School , 75 Francis Street, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9456-850X","authenticated-orcid":false,"given":"Vera A","family":"Bittner","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Disease, University of Alabama at Birmingham , Birmingham, AL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chern-En","family":"Chiang","sequence":"additional","affiliation":[{"name":"General Clinical Research Center and Division of Cardiology, Taipei Veterans General Hospital and National Yang-Ming University , Shih-Pai Road, 11217 Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1634-9402","authenticated-orcid":false,"given":"Roger M","family":"Correa Flores","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cardiology, Alberto Sabogal Sologuren , ESSALUD, Jir\u00f3n Colina 1081, Bellavista - Callao, Lima CA01, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Diaz","sequence":"additional","affiliation":[{"name":"Cardiology Department, Instituto Cardiovascular de Rosario , Paraguay 160, Santa Fe, Rosario 2000, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Dorobantu","sequence":"additional","affiliation":[{"name":"Cardiology Department, Emergency Clinical Hospital of Bucharest , 8 Calea Floreasca, ET 6 014461 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8068-2440","authenticated-orcid":false,"given":"Shaun G","family":"Goodman","sequence":"additional","affiliation":[{"name":"Canadian VIGOUR Centre, University of Alberta , 87 Ave NW, Edmonton, Alberta T6G 2E1, Canada"},{"name":"Division of Cardiology, St. Michael's Hospital, University of Toronto , 30 Bond Street, Toronto, Ontario M5B 1W8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Wouter","family":"Jukema","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leiden University Medical Center , PO Box 9600, 2300 RC Leiden, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Un","family":"Kim","sequence":"additional","affiliation":[{"name":"R&D Clinical Development , Sanofi, 1 avenue Pierre Brossolette, 91380 Chilly-Mazarin, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8001-6795","authenticated-orcid":false,"given":"Robert","family":"Pordy","sequence":"additional","affiliation":[{"name":"Clinical Sciences - Cardiovascular & Metabolism Therapeutics, Regeneron Pharmaceuticals Inc. , 777 Old Saw Mill River Rd, Tarrytown, NY 10591, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T","family":"Roe","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Division of Cardiology, Duke University Medical Center , 200 Morris Street, Durham, NC 27701, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rody G","family":"Sy","sequence":"additional","affiliation":[{"name":"Cardiovascular Institute, Cardinal Santos Medical Center , Wilson Street, San Juan, 1502 Metro Manila, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0046-0264","authenticated-orcid":false,"given":"Michael","family":"Szarek","sequence":"additional","affiliation":[{"name":"Downstate School of Public Health, State University of New York , 450 Clarkson Avenue, MS 43, Brooklyn, NY 11203 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7712-6750","authenticated-orcid":false,"given":"Harvey D","family":"White","sequence":"additional","affiliation":[{"name":"Green Lane Cardiovascular Services , Auckland 20 City Hospital, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas M","family":"Zeiher","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Goethe University , Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6896-2941","authenticated-orcid":false,"given":"Ph Gabriel","family":"Steg","sequence":"additional","affiliation":[{"name":"Hopital Bichat, Universite\u00e9 de Paris, FACT (French Alliance for Cardiovascular Trials), INSERM U1148, Assistance Publique-Hopitaux de Paris , Paris, France"},{"name":"National Heart and Lung Institute, Imperial College , Royal Brompton Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the ODYSSEY OUTCOMES Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,11,16]]},"reference":[{"key":"2022102611184133200_ehz809-B1","doi-asserted-by":"crossref","first-page":"e007061.","DOI":"10.1161\/JAHA.117.007061","article-title":"Impact of aging on the strength of cardiovascular risk factors: a longitudinal study over 40 years","volume":"7","author":"Lind","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2022102611184133200_ehz809-B2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","year":"2019","journal-title":"Lancet"},{"key":"2022102611184133200_ehz809-B3","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1016\/j.jacc.2016.03.004","article-title":"Knowledge gaps in cardiovascular care of the older adult population: a scientific statement from the American Heart Association","volume":"67","author":"Rich","year":"2016","journal-title":". J Am Coll Cardiol"},{"key":"2022102611184133200_ehz809-B4","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1016\/j.jacc.2018.08.2191","article-title":"Switching, discontinuation, and reinitiation of statins among older adults","volume":"72","author":"Ofori-Asenso","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022102611184133200_ehz809-B5","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/jamacardio.2018.4936","article-title":"Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease","volume":"4","author":"Rodriguez","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2022102611184133200_ehz809-B6","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12529-017-9691-y","article-title":"Secondary prevention in younger vs. older coronary heart disease patients-insights from the German Subset of the EUROASPIRE IV survey","volume":"25","author":"Wagner","year":"2018","journal-title":"Int J Behav Med"},{"key":"2022102611184133200_ehz809-B7","author":"Bach"},{"key":"2022102611184133200_ehz809-B8","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2022102611184133200_ehz809-B9","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2022102611184133200_ehz809-B10","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: a Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"2022102611184133200_ehz809-B11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102611184133200_ehz809-B12","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","article-title":"Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial","volume":"168","author":"Schwartz","year":"2014","journal-title":"Am Heart J"},{"key":"2022102611184133200_ehz809-B13","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.amjmed.2018.12.032","article-title":"Real-life benefits of statins for cardiovascular prevention in elderly subjects: a population-based cohort study","volume":"132","author":"Bezin","year":"2019","journal-title":"Am J Med"},{"key":"2022102611184133200_ehz809-B14","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1093\/eurheartj\/ehl180","article-title":"Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS","volume":"27","author":"Ray","year":"2006","journal-title":"Eur Heart J"},{"key":"2022102611184133200_ehz809-B15","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.amjcard.2006.09.111","article-title":"Effects of high-dose atorvastatin in patients &gt; or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study)","volume":"99","author":"Olsson","year":"2007","journal-title":"Am J Cardiol"},{"key":"2022102611184133200_ehz809-B16","doi-asserted-by":"crossref","first-page":"69.","DOI":"10.1007\/s10557-019-06852-6","article-title":"Impact of age on the efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia","volume":"33","author":"Ginsberg","year":"2019","journal-title":"Cardiovasc Drugs Ther"},{"key":"2022102611184133200_ehz809-B17","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/eurheartj\/ehx661","article-title":"No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data","volume":"39","author":"Harvey","year":"2018","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/41\/24\/2248\/46643239\/ehz809.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/41\/24\/2248\/46643239\/ehz809.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T11:21:06Z","timestamp":1666783266000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/41\/24\/2248\/5626150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,16]]},"references-count":17,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2019,11,16]]},"published-print":{"date-parts":[[2020,6,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehz809","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,6,21]]},"published":{"date-parts":[[2019,11,16]]}}}